Telix Pharmaceuticals Limited American Depositary Shares (TLX) Stock Price, News & Analysis

Company Overview

Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix Pharmaceuticals Limited is headquartered in Melbourne, Australia.

Key Stats

• Today's Range: $16.77 to $18.00
• 50-Day Range: $14.56 to $16.78
• 52-Week Range: $14.01 to $19.99
• Volume: 17,326 shs
• Average Volume: 11,035 shs
• Market Capitalization: $5.64 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Strong Buy

TLX Stock Analysis - Frequently Asked Questions

How have TLX shares performed this year?

Telix Pharmaceuticals Limited American Depositary Shares' stock was trading at $15.40 at the beginning of 2025. Since then, TLX shares have increased by 9.5% and is now trading at $16.86.
View the best growth stocks for 2025 here.

When did Telix Pharmaceuticals Limited American Depositary Shares IPO?

Telix Pharmaceuticals Limited American Depositary Shares (TLX) raised $202 million in an IPO on Friday, June 14th 2024. The company issued 17,000,000 shares at a price of $11.87 per share.

How do I buy shares of Telix Pharmaceuticals Limited American Depositary Shares?

Shares of TLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 1/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TLX
• Previous Symbol: NASDAQ:TLX
• CUSIP: N/A
• CIK: 2007191
• Web: www.telixpharma.com
• Phone: 61-3-9093-3855
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.00
• High Stock Price Target: $21.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: +24.6%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 334,720,000
• Free Float: N/A
• Market Cap: $5.64 billion
• Optionable: N/A
• Beta: N/A